NEW: Moderate to Severe Asthma Learning Zone launches on Medthority.com
Despite being a well-documented condition, Asthma can still prove challenging to healthcare professionals who want to identify the most effective approaches to optimizing management strategies.
We've developed the Moderate to Severe Asthma Learning Zone to help further your knowledge of moderate and severe asthma and its management, specific to stages 3-5 of the Global Initiative for Asthma (GINA) stepwise approach to asthma treatment.
Read on to get an overview of some of the educational resources now available online.
Top-up your learning or get a comprehensive overview to enhance your knowledge and understanding of asthma, including sections on the burden of the disease, classification and phenotyping and the symptoms.
How well do you understand the latest guidance for adult and paediatric asthma and asthma exacerbations?
Find out more
Take a deep-dive into the inflammatory cascade by discovering more about potential therapeutic targets, as well as the treatments for some cases of severe asthma.
Find out more
The Moderate to Severe Asthma Learning Zone has been developed by Medthority for Medthority.com, in collaboration with Novartis Pharma AG, with some content provided by Novartis Pharma AG (with the exception of the ERS Daily Blog content which has been created independently and with no input from the sponsor). Date of preparation: September 2019 (GLRESP/RESP/0337)
The Respiratory Care Learning Zone contains essential information on Inhaled Therapies in Asthma and COPD and its Management. The Learning Zone also has an Educational Resources section which features slide kits, congress news and webinars and videos relevant to asthma and COPD.
Related news and insights
GSK plc announced it will start Phase III trials of a low carbon version of its metered dose inhaler (MDI), Ventolin (salbutamol), using a next generation propellant, in 2024
The FDA's Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 16 to 1 that the data support a favourable benefit risk assessment for the use of PT 027 (albuterol/budesonide) for the treatment of asthma in people aged 18 years and older